Trial of Immunotherapy With Avelumab and Pepinemab As Second Line For Patients With Metastatic Pancreatic Adenocarcinoma
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT05102721 |
Recruitment Status :
Recruiting
First Posted : November 1, 2021
Last Update Posted : September 18, 2023
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Metastatic Pancreatic Adenocarcinoma | Drug: Avelumab and Pepinemab | Phase 1 Phase 2 |
Study Type : | Interventional (Clinical Trial) |
Estimated Enrollment : | 48 participants |
Allocation: | N/A |
Intervention Model: | Sequential Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Treatment |
Official Title: | A Phase 1b/2 Trial of Immunotherapy With Avelumab and Pepinemab As Second Line For Patients With Metastatic Pancreatic Adenocarcinoma |
Actual Study Start Date : | December 10, 2022 |
Estimated Primary Completion Date : | December 31, 2028 |
Estimated Study Completion Date : | December 31, 2028 |
Arm | Intervention/treatment |
---|---|
Experimental: Experimental
Single arm, all patients serially enrolled to combination doses of Avelumab and Pepinemab
|
Drug: Avelumab and Pepinemab
IV Infusions every two weeks. |
- Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability] [ Time Frame: 10 years ]Measured by adverse event severity and quantity
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Patient or legally acceptable representative must be able to understand and willing to sign an IRB approved written informed consent document.
- Patients must be 18 years or older
- Patients must have histologically confirmed metastatic pancreatic adenocarcinoma.
- Patients must have radiographically measurable disease defined as non-radiated lesions that can be accurately measured in at least one dimension (longest diameter to be recorded) as greater than or equal to 10mm with calipers by radiographic exam.Further details listed in section 5.5.
- Patients must have received 5FU or Gemcitabine based first line treatment (in combination with platinum, topoisomerase I inhibitor, or nab-paclitaxol) for metastatic disease with evidence of treatment failure or intolerance.
- If a subject received therapy in the adjuvant/neoadjuvant setting:
- Tumor recurrence must have occurred no sooner than 6 months after completion of the last dose of therapy.
- Radiation therapy for the locally advanced disease is allowed
- The patient must have a life expectancy of minimum 3 months.
-
Patient must have normal bone marrow and organ function as defined below:
- Absolute neutrophil count >1,500/mcl
- Platelets >100,000/mcl
- Hemoglobin >9.0 g/dL
- Creatinine should be below the upper limit of normal OR
- Creatinine clearance >60 mL/min/1.73 m2 for patients with creatinine levels above institutional normal
- Patient not on anticoagulation must have international Normalized Ratio (INR) and activated partial thromboplastin time (PTT) <1.5 upper limit of normal.
- Patient will have an ECOG performance status of 0, 1, or 2
- Patient must consent for baseline and on treatment biopsies, if prior baseline biopsies have been performed, and stored within the University of Rochester Cancer Library, then baseline biopsies are not necessary. Baseline biopsy must be of a lesion post-relapse.
- Patients with biliary stents for obstruction may be included in the study
- Female subjects of childbearing potential must demonstrate a negative urine or serum pregnancy test.
- Women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control, abstinence) prior to study entry and for the duration of the study treatment. Should a woman become pregnant or suspect she is pregnant while participating in this study, she must inform her treating physician immediately.
- Male subjects with a female partner of child-bearing potential must agree to use 2 adequate methods of contraception (barrier + hormonal for example).
Exclusion Criteria:
- Patient with any histologic variant of PDAC such as adenosquamous, acinar cell, duodenal adenocarcinoma, or ampullary adenocarcinoma
- Patient has a history of other malignancy ≤ 3 years previous with the exception of basal cell or squamous cell carcinoma of the skin which were treated with local resection only or carcinoma in situ of the cervix.
- Patient who is receiving or has received an investigational immunotherapy, investigational combinations of cytotoxic chemotherapy such as liposomal irinotecan are permitted
- Patient has a history of allergic reactions attributed to compounds of similar chemical or biologic composition to Pepinemab (VX15/2503) or Avelumab
- Patient with uncontrolled intercurrent illness including, but not limited to, ongoing or active infection symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, any clinically active malabsorption syndrome, inflammatory bowel disease, any condition that increases the risk of severe irinotecan gastrointestinal toxicity, or psychiatric illness/social situations that would limit compliance with study requirements
- Has an active autoimmune disease, or a documented history of autoimmune disease or a syndrome that requires steroids or immunosuppressive agents. Subjects with vitiligo or resolved childhood asthma/atopy would be exceptions to this rule.
- Has had an allogenic tissue/solid organ transplant.
- Has interstitial lung disease or a history of pneumonitis that required oral or intravenous glucocorticoids to assist with management.
- Has received or will receive a live vaccine within 30 days prior to the first administration of study medication. Flu vaccines that do not contain live virus are permitted.
- Has known active Hepatitis B or C.
- Patient who is pregnant and/or breastfeeding.
- Persisting toxicity related to prior anti-cancer therapy
- Major surgery or use of investigational drug within the 28 days before the start of treatment
- Current alcohol or drug abuse
- Prior organ or bone marrow transplantation
- Inability to comply with visit schedule or other protocol requirements including mandatory study biopsies
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT05102721
Contact: Chris Lefeber | 585-275-0407 | chris_lefeber@urmc.rochester.edu | |
Contact: Megan Boise, MS | mboise@vaccinex.com |
United States, New York | |
University of Rochester Medical Center | Recruiting |
Rochester, New York, United States, 14642 | |
Contact: Daniel Mulkerin, MD 585-275-6120 WCICTOResearch@urmc.rochester.edu | |
Principal Investigator: Daniel Mulkerin, MD |
Principal Investigator: | Daniel Mulkerin, MD | WCICTOResearch@urmc.rochester.edu |
Responsible Party: | Vaccinex Inc. |
ClinicalTrials.gov Identifier: | NCT05102721 |
Other Study ID Numbers: |
SGIP21027 |
First Posted: | November 1, 2021 Key Record Dates |
Last Update Posted: | September 18, 2023 |
Last Verified: | September 2023 |
Individual Participant Data (IPD) Sharing Statement: | |
Plan to Share IPD: | Yes |
Plan Description: | A complete and final study protocol will be made publicly available through the University of Rochester Cancer Center Community Oncology Research Program Research Base Protocol and Data Sharing Committee. The full protocol and data will be made publicly available no later than the publication date of the study findings from the final dataset. The protocol will include a detailed description of the study population, hypotheses tested, measurement and assessment information, data definitions and codes, and the analysis plan utilized. We will be collecting identifying information. The final dataset will be stripped of identifiers prior to release for sharing. Published papers will be made available in portable document format. |
Time Frame: | The data will be available for 7 years from accrual of the first subject |
Studies a U.S. FDA-regulated Drug Product: | Yes |
Studies a U.S. FDA-regulated Device Product: | No |
Metastatic Pancreatic Adenocarcinoma |
Adenocarcinoma Carcinoma Neoplasms, Glandular and Epithelial Neoplasms by Histologic Type |
Neoplasms Avelumab Antineoplastic Agents, Immunological Antineoplastic Agents |